SCHEDULE: TCG Crossover Discloses 9.8% Stake in InflaRx N.V.

TCG Crossover Fund III, L.P. and associated entities have reported a 9.8% beneficial ownership stake in InflaRx N.V. following a recent underwritten offering.

Summary

• TCG Crossover Fund III, L.P., TCG Crossover GP III, LLC, and Chen Yu have filed a Schedule 13G reporting collective beneficial ownership of 14,500,000 ordinary shares of InflaRx N.V.
• The reported stake represents 9.8% of the company's total outstanding common stock.
• The ownership position was established following an underwritten offering that closed on May 7, 2026.
• The reporting persons state that the shares were not acquired for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral disclosure of institutional ownership, reflecting standard market participation rather than a strategic shift or operational update.

Positives

• The filing indicates significant institutional investment interest in InflaRx N.V. following its recent capital raise.

Negatives

• The disclosure highlights a concentrated ownership position by a single investment group, which may impact future liquidity or voting dynamics.

Risks

• The reporting persons disclaim status as a group but acknowledge shared voting and dispositive power, which could lead to coordinated actions regarding the issuer.

Future Outlook

The reporting persons have certified that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that this filing reflects typical institutional activity in the biotechnology sector, where large crossover funds often participate in follow-on offerings to maintain or increase their stakes in clinical-stage companies.

Comparison to Industry Standards

• The 9.8% stake is consistent with standard institutional investment patterns for mid-cap biotechnology firms.
• The filing follows standard SEC disclosure requirements for investors crossing the 5% ownership threshold.

Related Party Transactions

• The filing notes that general and limited partners of the reporting entities may be deemed to have an interest in the proceeds from the sale of the issuer's securities.

Stakeholder Impact

• Existing shareholders should note the concentration of ownership, which may influence future shareholder votes.

Next Steps

• The reporting persons will be required to file amendments to this Schedule 13G if there are material changes in their percentage of ownership.

Key Dates

Keywords

InflaRx, Schedule 13G, TCG Crossover, Institutional Ownership, Biotech Investment, Equity Disclosure